Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice
about
P1343
The Promise of Preventive Cancer VaccinesCancer vaccines: state of the art of the computational modeling approachesCancer immunopreventionConcordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesionsIntratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cellsIL-12 and IL-27 sequential gene therapy via intramuscular electroporation delivery for eliminating distal aggressive tumors.Modeling the competition between lung metastases and the immune system using agents.In vivo evidence of htid suppressive activity on ErbB-2 in breast cancers over expressing the receptorThe IL-12Rbeta2 gene functions as a tumor suppressor in human B cell malignancies.Susceptibility to polyomavirus-induced tumors in inbred mice: role of innate immune responses.New insights into IL-12-mediated tumor suppression.Optimal vaccination schedule search using genetic algorithm over MPI technologyMathematical modeling of the immune system recognition to mammary carcinoma antigen.Vaccines targeting the neovasculature of tumorsIL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells.Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas.Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma.Plant virus particles carrying tumour antigen activate TLR7 and Induce high levels of protective antibody.Oncoantigens for an immune prevention of cancer.The antigenic repertoire of premalignant and high-risk lesions.Endogenous IL-12 triggers an antiangiogenic program in melanoma cells.Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis.Intradermal DNA Electroporation Induces Cellular and Humoral Immune Response and Confers Protection against HER2/neu Tumor.A vaccine targeting angiomotin induces an antibody response which alters tumor vessel permeability and hampers the growth of established tumorsDefects in the interferon-gamma and interleukin-12 pathways.The promise of genetically engineered mice for cancer prevention studies.Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapyTriggering CD40 on endothelial cells contributes to tumor growthThe antitumor effects of adenoviral-mediated, intratumoral delivery of interleukin 23 require endogenous IL-12.Local delivery of recombinant vaccinia virus encoding for neu counteracts growth of mammary tumors more efficiently than systemic delivery in neu transgenic miceGenetic susceptibility of cervical cancer.Preclinical HER-2 Vaccines: From Rodent to Human HER-2Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune responseImmune surveillance: a balance between protumor and antitumor immunity.Reengineering dendritic cell-based anti-cancer vaccines.Twelve immunotherapy drugs that could cure cancers.Her-2 DNA versus cell vaccine: immunogenicity and anti-tumor activity.Adenoviral-mediated, intratumor gene transfer of interleukin 23 induces a therapeutic antitumor responseChemo-immunotherapy induces tumor regression in a mouse model of spontaneous mammary carcinogenesis.Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice.
P2860
Q26783742-1468D87D-41C5-4B2D-B708-61FC9DA28BB4Q26825044-19F7D2B2-AA0E-495B-BC72-548E1C300EBCQ28303393-E9989FDF-C451-487D-A1DD-A3374CBCDC17Q30909247-6A0667A2-C917-482E-BB2D-E60105BC2C9DQ33645792-4B1FFE26-5D6F-443B-A644-61879E4DC323Q33670036-B455D73D-E293-4481-BCA7-B8E91A9DF360Q33755575-0305D9A6-BD8D-49BE-9349-39297C31504BQ34016590-7135E1E1-9176-4481-B64D-5553AA368506Q34327974-2D577114-E3EC-42E9-ACE1-068F336BA1DBQ34347714-FDDDA1E5-00B0-4A6D-8273-10340ECA757FQ34436897-D75E8A5B-2AD8-435E-A136-F195C5369079Q34475889-07DF840D-5C3B-4527-B309-644F97624A55Q34529999-5BFDE894-B058-4C74-BAAF-2A4886D03A13Q34704905-37F0B3EB-DAF6-4B6D-BF6D-69EF25D7B58AQ34798580-7C7C151A-B762-42C2-B571-C2670DAC504EQ34912810-C158875D-9AF0-442E-A189-E645617F967FQ35083847-F327D9E2-4915-4D99-8B38-462139D9CBA3Q35096289-AA7303FB-D387-442E-8E04-5521D9CA625DQ35232253-1345E2A9-930F-4615-AE24-402FAB6E4421Q35251460-A66130C3-5551-4F45-B207-B7F827D363AFQ35676753-E5C3DFE3-C427-4371-9B38-F74FDF14751CQ35710332-F15309EC-C889-4106-844B-E47BD82C87B3Q35890518-AA4FB356-0628-415F-B33B-0F63741E0A42Q35918770-C5F531B4-F148-477A-BB3F-7C973C1BD2CBQ36015012-D42B5348-FAB3-4AD3-B3E2-A9A159BCB2B6Q36058466-D24BA0A9-401C-4F1B-ACA6-3B5B351AFEAEQ36116250-3319B668-6176-44EF-8A32-27A09DF8AEEBQ36228064-0E8511FF-2188-48AE-B07C-E1CE8F1EA3D7Q36430077-DFC1EF7F-4C37-4954-BE82-C925E6CEC636Q36580203-87A9888E-F8F2-43DF-8905-94A17C1283A5Q36683202-B0D96174-8989-400C-B7C8-89603CCF0B73Q36914661-62C10294-3BE8-4BE4-9391-8CDAB467C9A1Q36945070-C3D254D0-6B42-4483-8B0C-BE5AE445E6A9Q37097545-0B30D535-050B-4C26-A75E-A21251A2F96AQ37118177-8AF09A2B-CA0A-49FC-8BB2-4729C38EC3A7Q37118201-84E6A09E-D657-465E-A7BE-95C985A71E3DQ37307584-047631C2-EB7C-4433-9DCA-67254F857FC3Q37350345-B2E231D2-6E19-41F0-B43D-A5BE1754E671Q37644937-F1ADB6A9-58A3-4BC1-8619-2BA817EE0EA7Q37649642-104CA6D4-A8D6-4FD8-B501-FA82D4A71293
P2860
Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Combined allogeneic tumor cell ...... s in HER-2/neu transgenic mice
@ast
Combined allogeneic tumor cell ...... s in HER-2/neu transgenic mice
@en
Combined allogeneic tumor cell ...... s in HER-2/neu transgenic mice
@nl
type
label
Combined allogeneic tumor cell ...... s in HER-2/neu transgenic mice
@ast
Combined allogeneic tumor cell ...... s in HER-2/neu transgenic mice
@en
Combined allogeneic tumor cell ...... s in HER-2/neu transgenic mice
@nl
prefLabel
Combined allogeneic tumor cell ...... s in HER-2/neu transgenic mice
@ast
Combined allogeneic tumor cell ...... s in HER-2/neu transgenic mice
@en
Combined allogeneic tumor cell ...... s in HER-2/neu transgenic mice
@nl
P2093
P2860
P50
P356
P1476
Combined allogeneic tumor cell ...... s in HER-2/neu transgenic mice
@en
P2093
C De Giovanni
E Di Carlo
G Nicoletti
L Landuzzi
M P Colombo
P L Lollini
P2860
P304
P356
10.1084/JEM.194.9.1195
P407
P4510
P577
2001-11-05T00:00:00Z